Lancet Rheumatology最新文献_第10页

Efficacy of combined immunomodulators in preventing uveitis relapses in patients with Behçet's disease on corticosteroids – Authors' reply 联合免疫调节剂在预防使用皮质类固醇的贝赫切特病患者葡萄膜炎复发方面的疗效 - 作者的回复

IF 15 1区医学

Lancet Rheumatology Pub Date : 2024-11-25 DOI: 10.1016/S2665-9913(24)00301-1

Zhenyu Zhong , Peizeng Yang

引用次数: 0

Understanding the spectrum from preclinical psoriatic arthritis to early diagnosis of the disease 了解从临床前银屑病关节炎到疾病早期诊断的整个过程。

IF 15 1区医学

Lancet Rheumatology Pub Date : 2024-11-20 DOI: 10.1016/S2665-9913(24)00268-6

Prof Francesco Ciccia MD PhD , Saviana Gandolfo MD , Prof Roberto Caporali MD PhD , Prof Jose U Scher MD

{"title":"Understanding the spectrum from preclinical psoriatic arthritis to early diagnosis of the disease","authors":"Prof Francesco Ciccia MD PhD , Saviana Gandolfo MD , Prof Roberto Caporali MD PhD , Prof Jose U Scher MD","doi":"10.1016/S2665-9913(24)00268-6","DOIUrl":"10.1016/S2665-9913(24)00268-6","url":null,"abstract":"<div><div>Psoriasis is a chronic inflammatory skin disease that often precedes the development of psoriatic arthritis. Advances over the past 10 years have deepened our understanding of the transition from skin inflammation to joint inflammation, revealing various phases during which genetic, environmental, and immunological factors can affect this transition. In 2023, a European Alliance of Associations for Rheumatology task force outlined key considerations for identifying individuals with subclinical disease from those with clinically stabilised disease. Discerning between subclinical psoriatic arthritis and very early disease is crucial and raises doubts and questions about when an individual transitions from being at risk to having established psoriatic arthritis. Labelling this stage as very early psoriatic arthritis rather than subclinical disease might have substantial clinical and therapeutic implications. This Viewpoint highlights the importance of precisely identifying the different stages of progression of psoriatic arthritis for timely interventions and better outcomes for patients.</div></div>","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 3","pages":"Pages e208-e211"},"PeriodicalIF":15.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Coronary polyarteritis nodosa. 冠状动脉多发性结节炎

IF 15 1区医学

Lancet Rheumatology Pub Date : 2024-11-19 DOI: 10.1016/S2665-9913(24)00305-9

Yi-Ning Yen, Hsien-Tzung Liao

引用次数: 0

Una Makris: What matters to older patients, matters most to her Una Makris：对老年患者来说，什么是最重要的，对她来说就是最重要的。

IF 15 1区医学

Lancet Rheumatology Pub Date : 2024-11-11 DOI: 10.1016/S2665-9913(24)00342-4

Jules Morgan

引用次数: 0

Palliative care in patients with rheumatic diseases 风湿病患者的姑息治疗。

IF 15 1区医学

Lancet Rheumatology Pub Date : 2024-11-11 DOI: 10.1016/S2665-9913(24)00238-8

Bjoern Buehring , Sen Hee Tay , Erika Manu , Raymond Yung

引用次数: 0

Understanding the multiple dimensions of ageing: 5Ms for the rheumatologist 了解老龄化的多重维度：风湿病学家的 5Ms。

IF 15 1区医学

Lancet Rheumatology Pub Date : 2024-11-11 DOI: 10.1016/S2665-9913(24)00230-3

Bjoern Buehring MD , Marloes van Onna MD , Prof Elena Myasoedova MD , Jiha Lee MD , Una E Makris MD

{"title":"Understanding the multiple dimensions of ageing: 5Ms for the rheumatologist","authors":"Bjoern Buehring MD , Marloes van Onna MD , Prof Elena Myasoedova MD , Jiha Lee MD , Una E Makris MD","doi":"10.1016/S2665-9913(24)00230-3","DOIUrl":"10.1016/S2665-9913(24)00230-3","url":null,"abstract":"<div><div>The global population is ageing and the rheumatology workforce should be prepared to take care of the inevitable complexities of ageing patients. We can learn from our colleagues and experts in geriatrics about how best to manage multimorbidity, polypharmacy, geriatric syndromes, and shifting priorities of older patients in the context of delivering care for rheumatic diseases. One approach to learning and adopting key ageing constructs within rheumatology practice is to incorporate the established Geriatric 5Ms—principles fundamental to caring for older adults. In this Series paper we discuss the 5Ms in the context of rheumatology practice (1) multicomplexity: assessing and managing multimorbidity and challenging biopsychosocial situations, (2) medications: ensuring that medications do not interfere with the other Ms, (3) mind: managing neurocognitive disorders and comorbid mental health conditions, (4) mobility: ensuring older adults can move independently and safely, and (5) what matters most: aligning care with an older adult's specific goals.</div></div>","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"6 12","pages":"Pages e892-e902"},"PeriodicalIF":15.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cognitive impairment in individuals with rheumatic diseases: the role of systemic inflammation, immunomodulatory medications, and comorbidities 风湿病患者的认知障碍：全身炎症、免疫调节药物和合并症的作用。

IF 15 1区医学

Lancet Rheumatology Pub Date : 2024-11-11 DOI: 10.1016/S2665-9913(24)00190-5

Prof Elena Myasoedova MD , Sebastian E Sattui MD MS , Jiha Lee MD MHS , Prof John T O'Brien DM , Una E Makris MD MSc

{"title":"Cognitive impairment in individuals with rheumatic diseases: the role of systemic inflammation, immunomodulatory medications, and comorbidities","authors":"Prof Elena Myasoedova MD , Sebastian E Sattui MD MS , Jiha Lee MD MHS , Prof John T O'Brien DM , Una E Makris MD MSc","doi":"10.1016/S2665-9913(24)00190-5","DOIUrl":"10.1016/S2665-9913(24)00190-5","url":null,"abstract":"<div><div>Inflammation is an important risk factor, a potential therapeutic target for cognitive decline and dementia, and an inherent feature of autoimmune and immune-mediated rheumatic diseases. The risk of cognitive impairment and dementia is increased in individuals with immune-mediated rheumatic diseases, particularly in those with cardiovascular risk factors and cardiovascular disease. Immunomodulatory medications have been associated with a reduced risk of dementia, but whether this effect is mediated through their anti-inflammatory immunomodulating properties or other mechanisms, such as cardiovascular risk reduction, is unclear. A better understanding of the role of chronic inflammation as a modifiable risk factor for cognitive performance in rheumatic diseases will help inform opportunities for the management of cognitive impairment in people with rheumatic diseases and other chronic inflammatory diseases. In this Series paper, we discuss the epidemiology, risk factors, and current evidence on the role of immunomodulatory medications in cognitive impairment and dementia in people with rheumatic diseases.</div></div>","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"6 12","pages":"Pages e871-e880"},"PeriodicalIF":15.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ageism and rheumatic diseases 老龄化与风湿病

IF 15 1区医学

Lancet Rheumatology Pub Date : 2024-11-11 DOI: 10.1016/S2665-9913(24)00239-X

Devyani Misra , Bjoern Buehring , Raymond Yung , Una E Makris

引用次数: 0

Frailty and rheumatic diseases: evidence to date and lessons learned 虚弱与风湿病：迄今为止的证据与经验教训。

IF 15 1区医学

Lancet Rheumatology Pub Date : 2024-11-11 DOI: 10.1016/S2665-9913(24)00191-7

Sarah B Lieber MD , Katherine D Wysham MD , Sebastian E Sattui MD , Prof Raymond Yung MBChB , Devyani Misra MBBS MS

{"title":"Frailty and rheumatic diseases: evidence to date and lessons learned","authors":"Sarah B Lieber MD , Katherine D Wysham MD , Sebastian E Sattui MD , Prof Raymond Yung MBChB , Devyani Misra MBBS MS","doi":"10.1016/S2665-9913(24)00191-7","DOIUrl":"10.1016/S2665-9913(24)00191-7","url":null,"abstract":"<div><div>Frailty represents a dynamic multisystem state of reduced physiological reserve that increases vulnerability to adverse health outcomes. Frailty occurs prematurely in adults with immune-mediated rheumatic diseases and is emerging as an important risk factor for adverse outcomes in these conditions. In this Series paper, we present a conceptual overview of frailty and its prevalence among patients with immune-mediated rheumatic diseases. We discuss putative mechanisms of frailty relevant to these diseases, tools for frailty measurement, and potential implications of frailty assessment for clinical care. We also explore the complex inter-relationship between frailty, inflammation, and disease activity in immune-mediated rheumatic diseases. As insight is gained into the epidemiology and mechanisms of frailty among patients with immune-mediated inflammatory rheumatic diseases, the possibility of targeting frailty with an intervention that could complement standard disease-modifying therapies to prevent adverse outcomes and improve health-related quality of life becomes closer to reality.</div></div>","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"6 12","pages":"Pages e881-e891"},"PeriodicalIF":15.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Are we ready for home spirometry for systemic sclerosis-associated ILD? 我们准备好用家庭肺活量法治疗系统性硬化症相关的 ILD 吗？

IF 15 1区医学

Lancet Rheumatology Pub Date : 2024-11-08 DOI: 10.1016/S2665-9913(24)00266-2

Jessica Channick , Elizabeth R Volkmann

引用次数: 0